Atherogenic Dyslipidaemia in Diabetes: Burden and Challenges.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and clinical management without primary data
What was done
This is a narrative review summarizing the pathophysiological mechanisms, clinical burden, and pharmacological management of atherogenic dyslipidemia in patients with type 2 diabetes, metabolic syndrome, and obesity.
What was found
The abstract provides no numerical findings or effect sizes. It describes the characteristic lipid triad (high triglycerides, low HDL-C, and elevated small dense LDL particles) and notes that lifestyle modification alongside lipid-lowering therapies (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) are used to manage atherosclerotic cardiovascular risk.
Why it matters
It highlights the contribution of remnant lipoproteins and triglyceride-rich particles to residual cardiovascular disease risk in insulin-resistant states.
Limits
As a narrative review, it lacks a systematic literature search, meta-analytic pooling, and primary patient data. No comparative effect sizes or clinical outcome numbers are reported in the abstract.
Cited by
- supports Low HDL cholesterol levels are metabolically associated with increased levels of small, dense LDL particles.